The latest news from Corcept Therapeutics on their Phase 3 GRACE clinical trial clinical trial is excellent.
The drug relacorilant significantly reduced high blood pressure and blood sugar levels in people with endogenous Cushing’s syndrome. Relacorilant was tested in two phase 3 clinical trials. This new data comes from the open-label portion of the clinical trial. Click here to read more about Hypercortisolism and Cushing’s.
Richard Auchus, MD, PhD, Professor of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes at the University of Michigan and Chief of the Endocrinology & Metabolism Section at the Ann Arbor VA Medical Center said in a recent company press release, “Patients showed marked improvement across a broad range of signs and symptoms, without significant safety burden. Due to relacorilant’s unique mechanism of action, we are not observing other toxicities seen with current therapies, which positions relacorilant to potentially become a new standard of care for patients with this disease.”
In the Corcept press release, Bill Guyer, PharmD, Corcept’s Chief Development Officer, said Cushing’s syndrome has many signs and symptoms, which is why it is so important that patients in GRACE’s open-label phase exhibited improvements across a broad range of clinically meaningful endpoints. He added that they expect to build on these results in the trial’s randomized withdrawal phase and present data from the open-label and randomized withdrawal phases at a medical conference in June. The process remains on track to submit a New Drug Application (NDA) from the U.S. Food and Drug Administration (FDA) for a license to market the drug this quarter.
You can also access more Cushing’s content from Pituitary World News here.
© 2024, Pituitary World News. All rights reserved.